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Abstract Both clinical and preclinical studies demon-
strate the antidepressant activity of the functional NMDA
receptor antagonists. In this study, we assessed the effects
of two glycine/NMDA receptor ligands, namely L-701,324
(antagonist) and D-cycloserine (a partial agonist) on the
action of antidepressant drugs with different pharmaco-
logical proﬁles in the forced swim test in mice. Swim
sessions were conducted by placing mice individually in
glass cylinders ﬁlled with warmed water for 6 min. The
duration of behavioral immobility during the last 4 min of
the test was evaluated. The locomotor activity of mice was
measured with photoresistor actimeters. L-701,324 and
D-cycloserine given with reboxetine (administered in sub-
effective doses) did not change the behavior of animals in
the forced swim test. A potentiating effect was seen when
both tested glycine site ligands were given concomitantly
with imipramine or ﬂuoxetine in this test. The lesion of
noradrenaline nerve terminals produced by DSP-4 neither
altered the baseline activity nor inﬂuenced the antidepres-
sant-like action of L-701,324 or D-cycloserine. The deple-
tion of serotonin by p-CPA did not alter baseline activity in
the forced swim test. However, it completely antagonized
the antidepressant-like action produced by L-701,324 and
D-cycloserine. Moreover, the antidepressant-like effects of
imipramine, ﬂuoxetine and reboxetine were abolished by
D-serine, a full agonist of glycine/NMDA receptors. The
present study demonstrates that glycine/NMDA receptor
functional antagonists enhance the antidepressant-like
action of serotonin, but not noradrenaline-based antide-
pressants and such their activity seems to depend on
serotonin rather than noradrenaline pathway.
Keywords NMDA receptor  Glycine site  Lesion 
Antidepressants  Forced swim test  Mice
Introduction
Depression is a chronic recurring illness that affects more
than 120 million people worldwide. In industrialized
societies, approximately ﬁve percent of the population
experienced a major depressive episode. It is considered
that symptoms of depression result from perturbations in
monoaminergic neurotransmission. Thus, drugs currently
used for treatment of depression include medications that
modulate monoaminergic neurotransmission, primarily
serotonin and noradrenaline pathways. Unfortunately, their
efﬁcacies are unsatisfactory, they produce multiple
unwanted side effects and the mechanism of their antide-
pressant action remains not entirely elucidated (Hollister
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least 2–4 weeks to produce a clinically meaningful
improvement in depressive symptomatology (Rosenzweig-
Lipson et al. 2007); therefore, novel therapeutic strategies
are sought.
Over the past 20 years, numerous data demonstrated that
N-methyl-D-aspartate (NMDA) receptors may be involved
in the mechanism of action of antidepressant treatment
(Skolnick et al. 1996; Skolnick 1999; Skolnick et al. 2009).
In addition, signiﬁcantly higher serum and plasma levels of
glutamate in patients with depression than those of healthy
controls were reported (Kim et al. 1982; Altamura et al.
1993; Mauri et al. 1998; Nowak et al. 2003; Mitani et al.
2006; Siwek et al. 2009). Moreover, increased levels of
glutamate in the frontal cortex were demonstrated, impli-
cating abnormality of glutamatergic neurotransmission in
the pathophysiological features of major depressive disor-
der (Sanacora et al. 2004).
Extensive studies have shown that competitive and
noncompetitive NMDA receptor antagonists, polyamine
site antagonists and inorganic inhibitors of NMDA receptor
function, zinc and magnesium, produced antidepressant-
like activity in preclinical antidepressant screening proce-
dures (Trullas and Skolnick 1990; Maj et al. 1992a, b;
Moryl et al. 1993; Maj et al. 1994; Layer et al. 1995;
Kroczka et al. 2000, 2001; Nowak et al. 2003; Poleszak
et al. 2004; Nowak et al. 2006; Szewczyk et al. 2008;
Siwek et al. 2009). Furthermore, an antagonist of the
NMDA receptor complex, ketamine, and memantine are
effective in human depression (Berman et al. 2000; Zarate
et al. 2006a, b). Moreover, CP-101, 606 (a selective
antagonist of NR2B subunit of the NMDA receptor) and
zinc (non speciﬁc antagonist of NMDA receptor) enhance
efﬁcacy of antidepressant therapy in major depression
(especially treatment resistant subtype) (Nowak et al. 2003;
Preskorn et al. 2008; Siwek et al. 2009). However, it should
be mentioned that there is a discrepancy between long-term
effects of ketamine in clinical observations and experi-
mental paradigms used to evaluate antidepressant activity
(e.g., Maeng et al. 2008; Popik et al. 2008; Bechtholt-
Gompf et al. 2011).
Unfortunately, both competitive and noncompetitive
NMDA antagonists induce severe side effects (Willetts
et al. 1990) that limit their applicability as antidepressants
for clinical use in humans. Thus, an alternative strategy to
the use of competitive and noncompetitive NMDA antag-
onist was modulation of the glycine co-agonist site at the
NMDA receptor (Kemp and Leeson 1993).
Numerous behavioral studies have shown that antago-
nists and partial agonists at the glycine site exhibit anti-
depressant-like activity in experimental screening
procedures (Trullas and Skolnick 1990; Przegalin ´ski et al.
1997; Vamvakides 1998). Consequently, in this study, we
assessed the effects of two glycine B receptor ligands,
namely L-701,324 (antagonist) and D-cycloserine (a partial
agonist) on the action of antidepressant drugs with different
pharmacological proﬁles in the forced swim test in mice.
Materials and methods
Animals
The experiments were carried out on adult male Albino
Swiss mice (25–30 g) purchased from the licensed breeder
(Kołacz, Warsaw, Poland). The animals were kept in cages
(up to 10 per cage) on a natural day–night cycle with free
access to food and water and they were used after 7 days of
acclimatization to laboratory conditions. Each experimen-
tal group consisted of 8–12 animals. The experimental
protocol was approved by the Local Ethics Committee at
the Medical University of Lublin (license number
31/2007), and all the procedures were in strict compliance
with the European Communities Council Directive of 24
November 1986 (86/609/EEC).
Drug administration
L-701,324 [7-chloro-4-hydroxy-3-(3-phenoxy)phenylquin-
olin-2(1H)-one, Sigma] was suspended in a 1% aqueous
solution of Tween 80 and administered intraperitoneally
(i.p.) 60 min before the tests. D-cycloserine (DCS, D-4-
amino-3-isoxazolidone, Sigma) and antidepressant drugs:
imipramine (IMI, Sigma), ﬂuoxetine (FX, kindly provided
by Polpharma, Starogard Gdan ´ski, Poland) and reboxetine
(RB, Sigma) were dissolved in 0.9% saline freshly before
use and administered 60 min before the tests. Control
animals received an i.p. injection of saline (vehicle).
D-serine (Sigma, USA) was administered intracerebroven-
tricularly (i.c.v.) 15 min before the test. The i.c.v. admin-
istration was performed according to a modiﬁed method
described by Lipman and Spencer (1980). Brieﬂy, a 10-ll
glass Hamilton microsyringe (type 701) was used. The
needle (26 G) was shortened to a length of 7 mm, sharp-
ened and polished to a ﬁne tip. Rigid PVC tubing was put
on the needle to limit its penetration to 3 mm. The injection
site was approximately 2 mm posterior to an imaginary
line intersecting the posterior extent of the orbits of the
eyes and 1 mm lateral to the midline. The control animals
received an i.p. and i.c.v. injections of saline (vehicle). The
volume of vehicles or drug solutions for i.p. and i.c.v.
administrations was 10 ml/kg and 5 ll per mouse,
respectively. Drug doses and pretreatment schedules were
taken from the literature and were conﬁrmed in our pre-
vious experiments (Poleszak et al. 2005b; Poleszak 2007;
Poleszak et al. 2007b; Szewczyk et al. 2010).
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In a separate series of experiments, in order to investigate
the possible contribution of serotonergic system to the
effect of DCS or L-701,324 in the FST, mice were treated
with p-chlorophenylalanine (p-CPA, Sigma). p-CPA is
known to be an inhibitor of serotonin biosynthesis and
depletes serotonin from the brain and other tissues by the
selective inhibition of tryptophane hydroxylase (Koe and
Weissman 1966; Poleszak 2007). In the present experi-
ments, the mice were injected i.p. either with saline or with
p-CPA. p-CPA was dissolved in 0.9% saline and admin-
istered at a dose of 200 mg/kg once daily for 3 consecutive
days. On the fourth day, the mice received DCS, L-701,324
or saline injections 60 min before testing.
Noradrenergic lesion
In a separate series of experiments, in order to investigate
the possible contribution of noradrenergic system to
the effect DCS or L-701,324 in the FST, mice were
pretreated with N-(2-chloroethyl)-N-ethyl-2-bromobenzyl-
amine hydrochloride (DSP-4, Sigma)—a selective nora-
drenergic neurotoxin (Matsumoto et al. 1995). In the
present experiments, the mice were pretreated i.p. with
saline or with DSP-4. DSP-4 was dissolved in 0.9% saline
and administered at a dose of 50 mg/kg 4 days prior to the
test. On the day of testing, the mice received DCS,
L-701,324 or saline injections 60 min before testing.
Forced swim test (FST)
The studies were carried out on mice according to the
method of Porsolt et al. (1977). Mice were placed indi-
vidually into glass cylinders (height 25 cm, diameter
10 cm) containing 10 cm of water, maintained at 23–25C.
The animals were left in the cylinder for 6 min. After the
ﬁrst 2 min, the total duration of immobility was measured
during a 4-min test with a summing stopwatch. The mouse
was judged to be immobile when it remained ﬂoating
passively in the water, performing slow motion to keep
head above the water.
Locomotor activity
The actimeter consists of a cylinder (30 cm diameter,
12 cm high, MultiServ, Lublin, Poland) equipped with two
perpendicular infrared light beams located 1.5 cm above
the ﬂoor. Mice were i.p. pretreated with respective drugs
combinations and after a given time period they were
placed in the actimeter and locomotor activity (number of
interruptions of light beams) was recorded for a period of
10 min after placing the mouse into the actimeter.
Statistical analysis
All experimental results are presented as the mean ± SEM.
Comparisons between control and experimental groups
were performed by analysis of variance (ANOVA) fol-
lowed by Student-Neuman-Keuls post hoc test, where
appropriate.P \0.05 was considered as a statistically
signiﬁcant difference.
Results
Forced swim test
Effect of joint administration of L-701,324 and IMI
in the FST
The effects of a combined administration of L-701,324 and
IMI on total duration of immobility in mice are shown in
Fig. 1a [ANOVA: F(3,30) = 6.670, p = 0.0014]. L-701,324
at a dose of 1 mg/kg had no effect on the immobility time in
mice. IMI given alone at a dose of 15 mg/kg was also inef-
fective.L-701,324(1 mg/kg)injectedincombinationwithIMI
(15 mg/kg)signiﬁcantly reducedtheimmobility time in mice.
Effect of joint administration of L-701,324 and FX
in the FST
The effects of a combined administration of L-701,324 and
FX on total duration of immobility in mice are shown in
Fig. 1b[ANOVA:F(3,31) = 11.59,p\0.0001].L-701,324
at a dose of 1 mg/kg had no effect on the immobility time in
mice. FX given alone at a dose of 5 mg/kg was also ineffec-
tive. L-701,324 (1 mg/kg) injected in combination with FX
(5 mg/kg) signiﬁcantly reduced the immobility time in mice.
Effect of joint administration of L-701,324 and RB
in the FST
TheeffectsofcombinedadministrationofL-701,324andRB
on total duration of immobility in mice are shown in Fig. 1c
[ANOVA: F(3,29) = 0.2083, p = 0.8898]. L-701,324 at a
dose of 1 mg/kg had no effect on the immobility time in
mice. RB given alone at a dose of 2.5 mg/kg was also inef-
fective. L-701,324 (1 mg/kg) injected in combination with
RB (2.5 mg/kg) was ineffective in this test.
Effect of pretreatment with p-CPA on the antidepressant-
like activity of L-701,324 in the FST
The effects of L-701,324 and p-CPA on the behavior in the
FST are shown in Fig. 2a [ANOVA: F(3,33) = 7.629,
p = 0.0005]. In controls, L-701,324 (4 mg/kg) signiﬁcantly
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administration of p-CPA (200 mg/kg i.p. once a day for 3
consecutive days) did not alter baseline behavior during the
FST. However, depletion of serotonin completely blocked
the decrease of the immobility time elicited by L-701,324.
Effect of pretreatment with DSP-4 on the antidepressant-
like activity of L-701,324 in the FST
The effects of L-701,324 and DSP-4 on the behavior in the
FST are shown in Fig. 2b [ANOVA: F(3,35) = 7.833,
p = 0.0004]. In controls, L-701,324 (4 mg/kg) signiﬁ-
cantly reduced the immobility time in comparison with
saline. The administration of DSP-4 (50 mg/kg i.p.) did not
alter baseline behavior during the FST and did not change
the reduction of the immobility time elicited by L-701,324.
Effect of joint administration of DCS and IMI in the FST
TheeffectsofacombinedadministrationofDCSandIMIon
total duration of immobility in mice are shown in Fig. 3a
[ANOVA: F(3,35) = 5.016, p = 0.0054]. DCS at a dose of
2.5 mg/kghad noeffect ontheimmobilitytime inmice. IMI
given alone at the dose of 15 mg/kg was also ineffective.
DCS (2.5 mg/kg) injected in combination with IMI (15 mg/
kg) signiﬁcantly reduced the immobility time in mice.
Effect of joint administration of DCS and FX in the FST
The effects of a combined administration of DCS and FX on
total duration of immobility in mice are shown in Fig. 3b
[ANOVA: F(3,35) = 5.016, p = 0.0054]. DCS at a dose of
2.5 mg/kg had no effect on the immobility time in mice. FX
given alone at a dose of 5 mg/kg was also ineffective. DCS
(2.5 mg/kg) injected in combination with FX (5 mg/kg)
signiﬁcantly reduced the immobility time in mice.
Effect of joint administration of DCS and RB in the FST
The effects of a combined administration of DCS and RB
on total duration of immobility in mice are shown in
Fig. 3c [ANOVA: F(3,34) = 0.7426, p = 0.5341]. DCS at
a dose of 2.5 mg/kg had no effect on the immobility time in
mice. RB given alone at a dose of 2.5 mg/kg was also
ineffective. DCS (2.5 mg/kg) injected in combination with
RB (2.5 mg/kg) was ineffective in this test.
Effect of pretreatment with p-CPA on the antidepressant-
like activity of DCS in the FST
TheeffectsofDCSandp-CPAonthebehaviorintheFSTare
shown in Fig. 2c [ANOVA: F(3,33) = 10.47, p\0.0001].
In control animals, DCS (5 mg/kg) signiﬁcantly reduced the
immobility time in comparison with saline. The adminis-
tration of p-CPA (200 mg/kg i.p. once a day for 3 consecu-
tive days) did not alter baseline behavior during the FST.
However, depletion of serotonin completely blocked the
decrease of immobility time elicited by DCS.
Effect of pretreatment with DSP-4 on the antidepressant-
like activity of DCS in the FST
TheeffectsofDCSandDSP-4onthebehaviorintheFSTare
shown in Fig. 2d [ANOVA: F(3,28) = 6.11, p\0.0025].
Fig. 1 Effect of joint administration of L-701,324 and a imipramine
(IMI), b ﬂuoxetine (FX) or c reboxetine (RB) on the total duration of
immobility in the forced swim test in mice. L-701,324 and
antidepressant drugs were administered i.p. 60 min before the test.
The values represent means ± SEM of 8–9 mice. **p\0.01,
***p\0.001 versus control (vehicle-treated animals) (Student–
Newman–Keuls post hoc test)
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bility time in comparison with saline. The administration of
DSP-4 (50 mg/kg i.p. once a day for 3 consecutive days) did
notalterbaselinebehaviorduringtheFSTanddidnotchange
the reduction of immobility time elicited by DCS.
Effect of joint administration of D-serine and IMI
in the FST
TheeffectsofacombinedadministrationofIMIand D-serine
(the glycine B receptor agonist) on the total duration of
immobility in mice are shown in Fig. 4a [ANOVA:
F(3,33) = 12.74, p\0.0001]. IMI at a dose of 30 mg/kg
signiﬁcantly reduced the immobility time in mice. D-serine
alone,giveni.c.v.atadoseof100 nmol/mouse,hadnoeffect
ontheimmobilitytime.However,whencombinedwithIMI,
it abolished the IMI-induced antidepressant-like effect.
Effect of joint administration of D-serine and FX in the FST
The effects of a combined administration of FX and
D-serine on total duration of immobility in mice are shown
in Fig. 4b [ANOVA: F(3,35) = 20.74, p\0.0001]. FX at
a dose of 10 mg/kg signiﬁcantly reduced the immobility
time in mice. D-serine given alone at a dose of 100 nmol/
mouse i.c.v. had no effect on the immobility time; how-
ever, when combined with FX, it abolished the FX-induced
antidepressant-like effect.
Effect of joint administration of D-serine and RB in the FST
The effects of a combined administration of RB and
D-serine on total duration of immobility in mice are shown
in Fig. 4c [ANOVA: F(3,36) = 3.777, p = 0.0187]. RB at
a dose of 5 mg/kg signiﬁcantly reduced the immobility
time in mice. D-serine given alone at a dose of 100 nmol/
mouse i.c.v. had no effect on the immobility time; how-
ever, when combined with RB, it abolished the RB-induced
antidepressant-like effect.
Locomotor activity
Effect of combined treatment with L-701,324
and antidepressant drugs (imipramine—IMI, reboxetine—
RB or ﬂuoxetine—FX) on spontaneous locomotor activity
in mice
Results presented in Table 1A of the effects of L-701,324,
IMI and RB on a locomotor activity were analyzed by
3-way ANOVA repeated measures (between-subjects fac-
tors of antidepressant, L-701,324 and repeated factor of
time). The administration of antidepressants did not affect
activity: F(2,48) = 1.98, NS; however, a co-treatment with
L-701,324 reduced activity: F(1,48) = 4.51, p\0.05.
There was also a signiﬁcant effect of time: F(1,48) =
32.99, p\0.0001. Since there were no signiﬁcant effects
of any interaction, the post hoc tests were not performed.
Results presented in Table 1B were analyzed by 2-way
repeated measures ANOVA (drug as a between groups
factor and time as a repeated measures factor) showed a
signiﬁcant effect of time: F(1,35) = 139.1, p\0.0001.
Administration of neither FX nor L-701,324 affected the
activity. However, there were signiﬁcant effects of inter-
actions between FX treatment and L-701,324 treatment:
F(1,35) = 5.35, p\0.05 as well as between L-701,324
treatment and time: F(1,35) = 5.46, p\0.05. These were
Fig. 2 The effects of pre-
treatment of animals with
p-CPA and DSP-4 on the
antidepressant-like effects of
a–b L-701,324 and c–d D-
cycloserine (DCS) in the forced
swim test in mice. p-CPA
(200 mg/kg, i.p.) was
administered once daily for 3
consecutive days. DSP-4 was
administered at a dose of
50 mg/kg 4 days prior to the
test. The values represent
means ± SEM of 9–10 mice.
**p\0.01, ***p\0.001
versus control (vehicle-treated
animals);
##p\0.01,
###p\0.001 versus, respective
glycine/NMDA ligand given
alone (Student–Newman–Keuls
post hoc test)
A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants 1539
123mostly due to a decrease in activity of L-701,324-treated
mice versus controls in the 10th min of activity measure-
ments (p\0.05, Newman-Keuls post hoc test).
Effect of D-cycloserine (DCS) and L-701,324
on spontaneous locomotor activity in DSP-4 and p-CPA-
lesioned mice
Results from Table 2A (analyzed by 2-way ANOVA
repeated measures) revealed signiﬁcant effects of DSP-4
treatment: F(1,40) = 4.2, p\0.05 and time: F(1,40) =
228.9, p\0.0001. There was also a signiﬁcant interaction
between DCS treatment and time: F(1,40) = 6.33,
p\0.05, mostly due to the fact that in the controls, DCS
reduced activity in the 5th min as compared with the
vehicle treatment in the 10th minute, while such an effect
was not observed in DSP-4-treated mice.
However, the two-way ANOVA repeated measures of
the data presented in the Table 2B and C demonstrated
only a signiﬁcant effect of time: F(1,38) = 92, p\0.0001
and F(1,54) = 137, p\0.0001, respectively.
Fig. 3 Effect of joint administration of D-cycloserine (DCS) and
a imipramine (IMI), b ﬂuoxetine (FX) or c reboxetine (RB) on the
total duration of immobility in the forced swim test in mice. DCS and
antidepressant drugs were administered i.p. 60 min before the test.
The values represent means ± SEM of 9–11 mice. **p\0.01 versus
control (vehicle-treated animals) (Student–Newman–Keuls post hoc
test)
Fig. 4 Effect of joint administration of D-serine (DS) and a imipra-
mine (IMI), b ﬂuoxetine (FX) or c reboxetine (RB) on the total
duration of immobility in the forced swim test in mice. DS was
administered intracerebroventricularly (i.c.v.) 15 min before the test
and antidepressant drugs were administered i.p. 45 min before DS.
The values represent means ± SEM of 9–12 mice. *p\0.05,
***p\0.001 versus control (vehicle-treated animals);
#p\0.05,
##p\0.01 versus respective antidepressant drug given alone
(Student–Newman–Keuls post hoc test)
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and antidepressant drugs (imipramine—IMI, Fluoxetine—
FX, reboxetine—RB) on spontaneous locomotor activity
in mice
Results presented in Table 3A analyzed by 2-way ANOVA
repeated measures showed a signiﬁcant effect of time:
F(1,36) = 231, p\0.0001 and a signiﬁcant interaction
between time, DCS and IMI treatments: F(1,36) = 8.23,
p\0.01. It appeared that at the 5th min, DCS reduced the
activity independently on IMI-co-administration, but at the
10th min of the test, DCS increased it in the controls but
decreased it in IMI-co-treated animals. However, the post
hoc test did not reveal any changes in activity as compared
with vehicle-vehicle controls.
Results presented in Table 3B and C analyzed by ana-
lyzed by 2-way ANOVA repeated measures showed that
only the time factor was signiﬁcant: F(1,35) = 257,
p\0.001 and F(1,36) = 331, p\0.0001, respectively.
Effect of combined treatment with D-serine (DS)
and antidepressant drugs (imipramine—IMI, ﬂuoxetine—
FX, reboxetine—RB) on spontaneous locomotor activity
in mice
Results presented in Table 4A analyzed by 3-way ANOVA
repeated measures showed a signiﬁcant effect of time:
F(1,48) = 113.6, p\0.0001 and of DS treatment:
F(1,48) = 10.38, p\0.01. The latter effects could be
attributed to a decrease in activity in DS-treated animals
independently of the time and the antidepressant treatment.
Results presented in Table 4B analyzed by 2-way
ANOVA repeated measures showed signiﬁcant effects of
time: F(1,34) = 126, p\0.0001 and of the interaction
between time and DS treatment: F(1,34) = 9.28, p\0.01.
The latter effect could be explained by a signiﬁcant
decrease in activity in the 10th min in DS ? RB group as
compared with RB treated group. However, the post hoc
test did not reveal any changes in activity as compared with
vehicle-treated controls.
Discussion
A growing amount of data supports the role of the excit-
atory glutamatergic neurotransmission in the pathophysi-
ology of depressive disorders. In the clinical studies,
disturbances of the glutamate level in depressed patients
were found (Mathis et al. 1988; Altamura et al. 1993;
Levine et al. 2000). The brain NMDA receptor abnormal-
ities in human suicide victims (Nowak et al. 1995) and
major depressives (Law and Deakin 2001; Karolewicz
Table 1 Effect of combined treatment with L-701,324 and antide-
pressant drugs on spontaneous locomotor activity in mice
Treatment Dose
(mg/kg)
Activity counts
5 min 10 min
A
Vehicle – 122.0 ± 8.9 190.1 ± 16.42
L-701,324 1 121.0 ± 9.78 172.1 ± 19.04
Imipramine 15 137.8 ± 11.09 207.6 ± 24.98
L-701,324 ? imipramine 1 ? 15 113.6 ± 21.26 142.9 ± 30.75
Reboxetine 2.5 113.3 ± 15.36 162.5 ± 21.71
L-701,324 ? reboxetine 1 ? 2.5 90.0 ± 12.04 127.9 ± 16.97
B
Vehicle – 153.1 ± 11.57 227.3 ± 18.58
L-701,324 1 125.1 ± 11.22 171.8 ± 19.22
Fluoxetine 5 132.5 ± 7.91 225.0 ± 13.29
L-701,324 ? ﬂuoxetine 1 ? 5 169.3 ± 14.0 234.2 ± 21.57
L-701,324, imipramine, ﬂuoxetine and reboxetine were administered
i.p. 60 min before the tests. Control animals received two i.p. injec-
tions of respective vehicles
The values represent means ± SEM of 8–10 mice
Table 2 Effect of D-cycloserine and L-701,324 on spontaneous
locomotor activity in DSP-4- and p-CPA-lesioned mice
Treatment Dose
(mg/kg)
Activity counts
5 min 10 min
A
Vehicle – 127.7 ± 12.69 190.5 ± 23.92
DSP-4 50 95.25 ± 8.66 143.3 ± 11.28
D-cycloserine 5 116.3 ± 10.43 199.7 ± 19.68
D-cycloserine ? DSP-4 5 ? 50 109.5 ± 8.60 181.3 ± 9.82
B
Vehicle – 114.4 ± 9.77 170.4 ± 16.31
DSP-4 50 123.6 ± 11.16 197.1 ± 14.41
L-701,324 4 136.6 ± 16.09 183.5 ± 27.12
L-701,324 ? DSP-4 4 ? 50 142.4 ± 13.03 201.8 ± 23.46
C
Vehicle – 138.4 ± 12.20 207.7 ± 21.91
p-CPA 200 120.3 ± 7.63 180.7 ± 15.27
D-cycloserine 5 118.7 ± 7.89 193.5 ± 9.92
D-cycloserine ? p-CPA 5 ? 200 119.0 ± 8.22 201.7 ± 15.90
L-701,324 4 129.5 ± 16.99 183.7 ± 35.18
L-701,324 ? p-CPA 4 ? 200 108.4 ± 13.37 182.5 ± 30.14
p-CPA (p-chlorophenylalanine, 200 mg/kg, i.p.) was administered
once daily for 3 consecutive days. DSP-4 (N-(2-chloroethyl)-N-ethyl-
2-bromobenzylamine hydrochloride) was administered i.p. at a dose
of 50 mg/kg 4 days prior to the test. D-cycloserine and L-701,324
were administered i.p. 60 min before the tests
The values represent means ± SEM of 10–12 mice
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were observed. Moreover, a noncompetitive NMDA
antagonist, ketamine, produced rapid and sustained anti-
depressant effects in depressed patients (Berman et al.
2000; Zarate et al. 2006a; Phelps et al. 2009; Price et al.
2009), as well as reports that riluzole, which inhibits glu-
tamate release, is effective in patients with bipolar
depression (Zarate et al. 2004, 2005). Recently, the anti-
depressant effect of NR2B subunit antagonist, traxoprodil
(CP-101, 606) was demonstrated in patients unresponsive
to a serotonin selective reuptake inhibitor (Kemp and
McKernan 2002; Preskorn et al. 2008).
Numerous reports from preclinical studies have docu-
mented the antidepressant-like activity of structurally
diverse NMDA receptor antagonists in animal behavioral
paradigms. Thus, NMDA channel blockers (dizocilpine), a
competitive antagonist of NMDA receptor (AP-7, CGP
37848), a polyamine site antagonist (eliprodil), divalent-
cation antagonists (Mg
2?,Z n
2?) and a glycine site antag-
onist (L-701,324), and partial agonist (DCS) were all active
in the FST (Skolnick et al. 1989; Trullas and Skolnick
1990; Kroczka et al. 2001; Paul and Skolnick 2003;
Poleszak et al. 2004, 2005a). Additionally, the glycine
partial agonist 1-aminocyclopropanecarboxylic acid
(ACPC) produced a more rapid onset of action in the
chronic mild stress model than it was typically observed for
biogenic-amine-based agents (Papp and Moryl 1996).
The glycine binding site is the regulatory domain of the
NMDA receptor complex with afﬁnity for the endogenous
ligands, glycine (or D-serine, another endogenous agonist
of the glycine site) (Wood et al. 1989, 1996). Activation of
this site by glycine or D-serine is absolutely required for
NMDA receptor activation by L-glutamate (Kemp and
Leeson 1993). It was proved that glycine receptor antag-
onists and partial agonists have favorable safety proﬁle
compared with competitive and noncompetitive NMDA
receptor antagonists (Hawkinson et al. 1997; Danysz and
Parsons 1998; Bordi et al. 1999; Beardsley et al. 2002)
making them a potential candidates for new antidepressant
drugs (Kemp and Leeson 1993; Danysz and Parsons 1998).
In the experimental screening procedures, both full
glycine antagonist (L-701,324) and partial agonists at the
glycine site (ACPC, DCS) exhibit activity comparable to
that of clinically used antidepressants (Trullas and
Table 3 Effect of combined treatment with D-cycloserine and anti-
depressant drugs on spontaneous locomotor activity in mice
Treatment Dose
(mg/kg)
Activity counts
5 min 10 min
A
Vehicle – 135.8 ± 9.32 193.7 ± 15.86
D-cycloserine 2.5 114.5 ± 14.10 216.1 ± 20.66
Imipramine (IMI) 15 121.0 ± 11.52 193.4 ± 11.99
D-cycloserine ? IMI 2.5 ? 15 110.3 ± 10.44 171.2 ± 18.87
B
Vehicle – 116.3 ± 7.29 175.4 ± 11.07
D-cycloserine 2.5 101.2 ± 8.07 164.2 ± 12.05
Fluoxetine (FX) 5 111.4 ± 7.15 174.3 ± 15.15
D-cycloserine ? FX 2.5 ? 5 111.0 ± 6.72 166.3 ± 11.93
C
Vehicle – 96.4 ± 8.24 156.0 ± 13.62
D-cycloserine 2.5 109.7 ± 7.28 183.5 ± 10.01
Reboxetine (RB) 2.5 99.5 ± 4.83 164.9 ± 11.05
D-cycloserine ? RB 2.5 ? 2.5 111.5 ± 6.11 182.4 ± 14.06
L-701,324, imipramine, ﬂuoxetine and reboxetine were administered
i.p. 60 min before the tests. Control animals received two i.p. injec-
tions of vehicle (saline)
The values represent means ± SEM of 9–10 mice
Table 4 Effect of combined
treatment with D-serine and
antidepressant drugs on
spontaneous locomotor activity
in mice
Imipramine, ﬂuoxetine and
reboxetine were administered
i.p. 60 min and D-serine was
administered i.c.v. 15 min
before the tests. Control animals
received saline in either two i.p.
injections or i.p. and i.c.v.
injections given at respective
times
The values represent
means ± SEM of 9–10 mice
Treatment Dose nmol/mouse
(i.c.v.)/mg/kg (i.p.)
Activity counts
5 min 10 min
A
Vehicle – 116.9 ± 7.95 182.9 ± 12.74
D-serine (i.c.v.) 100 75.67 ± 13.29 121.2 ± 19.04
Imipramine (i.p.) 30 110.1 ± 14.94 138.0 ± 20.34
D-serine ? imipramine 100 ? 30 73.0 ± 10.25 117.8 ± 11.93
Fluoxetine (i.p.) 10 121.9 ± 9.15 186.3 ± 15.60
D-serine ? ﬂuoxetine 100 ? 10 113.7 ± 11.32 148.0 ± 17.52
B
Vehicle – 91.33 ± 13.56 149.7 ± 20.0
D-serine (i.c.v.) 100 96.0 ± 8.26 141.1 ± 17.02
Reboxetine (i.p.) 5 101.7 ± 6.05 167.0 ± 7.45
D-serine ? reboxetine 100 ? 5 93.90 ± 10.48 119 7 ± 16.00
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123Skolnick 1990; Przegalin ´ski et al. 1997; Vamvakides
1998). In mice the effective dose of L-701,324 in this test
was 2 mg/kg (Przegalin ´ski et al. 1998), which was
conﬁrmed in our previous study (Poleszak et al. 2007a).
DCS, a partial agonist of glycine site of the NMDA
receptor complex (Hood et al. 1989) was also active in the
FST (an effect comparable to that observed with IMI
(Vamvakides 1998). Its antidepressant-like activity was
ﬁrst shown in tuberculosis patients (Kendig et al. 1956;
Lewis et al. 1957) and provides indirect support for the
hypothesis that glycine site partial agonists may be
potentially useful as antidepressants (Trullas and Skolnick
1990; Skolnick et al. 1992). As partial agonist DCS may
act as agonist or antagonist of the glycine B receptor
depending on the dose, that is, a lower dose acts as agonist
but higher doses act as antagonist of glycine binding site of
the NMDA receptor (Hood et al. 1989; Watson et al. 1990;
Emmett et al. 1991). In our previous study, the effective
dose of DCS in the FST was the dose 5 mg/kg, while the
lower dose (2.5 mg/kg) was not effective itself, but
potentiated the antidepressant effects of magnesium or zinc
(Poleszak et al. 2007b; Szewczyk et al. 2010).
In the present study, we have demonstrated the effects of
glycine site ligands (L-701,324 and DCS) on the action of
antidepressants with different pharmacological proﬁles:
IMI—a nonselective serotonin/noradrenaline reuptake
inhibitor (Westenberg 1999), FX—a selective serotonin
reuptake inhibitor (SSRI) (Rickels and Schweizer 1990)
and RB—a potent, selective, and speciﬁc noradrenergic
reuptake inhibitor (NARI) (Versiani et al. 1999).
L-701,324 and DCS given with RB (administered in sub-
effective doses) did not change the behavior of animals in
the forced swim test, the behavioral despair procedure
commonly used to detect antidepressant agents (Borsini
and Meli 1988). However, a potentiating effect was seen
when both tested glycine site ligands were given jointly
with IMI or FX in this test. This apparent potentiation was
manifested as a reduction of the immobility time, but no
increase in locomotor activity was evidenced. Similarly,
such interaction was demonstrated between ionic NMDA
antagonists zinc and magnesium with antidepressants in the
FST (Poleszak 2007; Szewczyk et al. 2009).
In the present study, in order to conﬁrm a possible
contribution of the serotonergic system to the antidepres-
sive effect of DCS and L-701,324, mice were pretreated
with p-CPA, an inhibitor of serotonin synthesis or with
DSP-4, a selective noradrenergic neurotoxin, and examined
in the FST. The lesion of noradrenaline nerve terminals
produced by DSP-4 did no alter the baseline activity or
inﬂuence antidepressant-like action caused by L-701,324
or DCS. The depletion of serotonin by p-CPA did not alter
baseline activity in the FST; however, completely antago-
nized the antidepressant-like action caused by L-701,324
and DCS. Thus, we proved that interaction with seroto-
nergic, but not noradrenergic system is necessary for
antidepressant-like activity of glycine/NMDA site ligands.
Our recent study has demonstrated that the activation of
the NMDA receptor complex by D-serine blocks the anti-
depressant-like effect of an antagonist of the glycine/
NMDA receptor L-701,324 and ionic antagonists, such as
zinc and magnesium, in the FST (Poleszak et al. 2007a, b,
2008). Now we show that the antidepressant-like effects of
IMI, FX and RB were abolished by D-serine pretreatment.
Thus, these data indicate that antidepressant activity of
both serotonin and noradrenaline-based antidepressant are
related to the mechanism connected with a reduction of the
activity of the NMDA receptor complex (particularly
glycine/NMDA sites). Contrary to this notion, Boulay et al.
(2008) demonstrated the antidepressant-like action of
glycine transporter type 1 inhibitor SSR103800 which may
indicate that activation of glycine/NMDA receptor is
related to an antidepressant activity. However, the glycine/
NMDA receptor dependence of the antidepressant-like
action of SSR103800 in the FST was not demonstrated
(e.g., antagonism by glycine/NMDA antagonists). The
discrepancy between present data and that of Boulay et al.
(2008) may also be due to the use of different species (mice
vs. rats, gerbils). The interaction between NMDA receptor
and serotonergic pathway is more obvious than NMDA
receptor and noradrenergic one (Yan et al. 1997). There is
emerging evidence that the interaction between excitatory
amino acids and serotonin may be important for the control
of many brain activities. Both NMDA and non-NMDA
receptor antagonists have been found to release serotonin
and to increase its turnover in some brain structures
(Lo ¨scher et al. 1993).
To summarize, the present study demonstrates complex
interaction between glycine/NMDA receptor ligands and
conventional serotonin/noradrenaline-based antidepres-
sants in the FST. While glycine/NMDA receptor functional
antagonists enhance an antidepressant-like action of sero-
tonin, but not noradrenaline-based antidepressants and their
such activity depends on serotonin but not noradrenaline
pathway, the antidepressant-like activity of both types of
antidepressants rely on the dampening of the NMDA
receptor complex. This study may provide some guidelines
about how to optimally use combinations of the NMDA
receptor antagonists and biogenic amine-based antide-
pressant drugs. The NMDA receptor antagonists as anti-
depressants may be on the near horizon, and the ability to
use lower doses of, e.g., traxoprodil when combined with
the appropriate agent may be an interesting approach to
antidepressant therapy.
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